Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parecoxib for hospitalized patients with spontaneous subarachnoid hemorrhage
2024-519436-17-00Phase 2Authorised
- Sponsor
- St. Anne's University Hospital Brno
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nontraumatic subarachnoid hemorrhage (SAH) comparing Parecoxib with Placebo (2 arms). Primary endpoint: Favorable functional outcome by modified Rankin Scale. Planned start Feb 2025; status: authorised.
02
Drugs
parecoxib
03
Conditions
nontraumatic subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2024-519436-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519436-17-00.